[Federal Register Volume 74, Number 8 (Tuesday, January 13, 2009)]
[Notices]
[Pages 1699-1700]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse; Special 
Emphasis Panel CEBRA Review.
    Date: January 16, 2009.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Mark Swieter, PhD, Chief, Training and Special 
Projects Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse. NIH, DHHS, 6101 Executive Boulevard, Suite 
220, Bethesda, MD 20892-8401, (301) 435-1389, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse; Special 
Emphasis Panel; Medications Development for Cannabis-Related 
Disorders.
    Date: January 29, 2009.
    Time: 8:30 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
[email protected].

    Name of Committee: National Institute on Drug Abuse; Special 
Emphasis Panel; Pilot Clinical Trials of Pharmacotherapies for 
Substance Related.
    Date: February 9, 2009.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Sofitel Hotel, 806 15th Street, NW., Washington, DC 
20005.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda. MD 20892-8401, 301-451-4530, [email protected].

    Name of Committee: National Institute on Drug Abuse, Initial 
Review Group, Health Services Research Subcommittee, NIDA-F.
    Date: February 10-11, 2009.
    Time: 8:30 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, 
DC 20037.
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
[email protected].
    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel,NIDA-F Conflicts.
    Date: February 10, 2009.
    Time: 3 p.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, 
DC 20037.
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401, 301-402-6626, [email protected].


[[Page 1700]]


    Name of Committee: National Institute on Drug Abuse, Special 
Emphasis Panel, NIDA-E Conflicts.
    Date: February 11, 2009.
    Time: 9 a.m. to 12 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, 
DC 20037.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401, 301-451-4530, [email protected].

    Name of Committee: National Institute on Drug Abuse; Initial 
Review Group; Medication Development Research Subcommittee.
    Date: February 12, 2009.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications
    Place: Double Tree Hotel, 1515 Rhode Island Avenue, NW., 
Washington, DC 20005.
    Contact Person: Jose F Ruiz, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, 6101 Executive Blvd., Rm. 213, MSC 8401, 
Bethesda, MD 20892, 301-451-3086, [email protected].

    Name of Committee: National Institute on Drug Abuse; Initial 
Review Group Training and; Career Development Subcommittee.
    Date: March 17-18, 2009.
    Time: 8:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 
20037.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, 
Bethesda, MD 20892-8401, 301-451-4530, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: January 5, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-280 Filed 1-12-09; 8:45 am]
BILLING CODE 4140-01-M